计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L333143-5mg |
5mg |
现货 ![]() |
| |
| L333143-10mg |
10mg |
现货 ![]() |
| |
| L333143-25mg |
25mg |
现货 ![]() |
| |
| L333143-50mg |
50mg |
现货 ![]() |
| |
| L333143-100mg |
100mg |
现货 ![]() |
| |
| L333143-250mg |
250mg |
现货 ![]() |
|
| 别名 | 洛斯马匹莫德 |
|---|---|
| 英文别名 | GS856553 | NSC785336 | NSC-785336 | HY-10402 | MFCD16619322 | F2DQF16BXE | GTPL7835 | BCP09909 | NSC800785 | NSC-800785 | SB68608 | 6-(5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl)-N-neopentylnicotinamide | 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl- |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Losmapimod |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | MAP 激酶 p38 beta 抑制剂 |
| 产品介绍 |
Losmapimod (GW856553X, GW856553, GSK-AHAB)是有效的选择性p38 MAPK抑制剂,其作用于p38α和p38β的pKi分别为8.1 和 7.6。P38 MAPKs涉及细胞分化、凋亡和自噬。Phase 3。 |
| pKa值 | pKa: 9.51 (Predicted), pKa: 2.22 (Predicted) |
|---|---|
| Ki Data | p38α: Ki= 7.94 nM (human); p38β: Ki= 25.12 nM (human) |
| IC50 | p38α: IC₅₀= 25.12 nM (human); CYP2C9: IC₅₀= 31.62 μM (human) |
| ALogP | 3.8 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504766542 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide |
| INCHI | InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28) |
| InChi Key | KKYABQBFGDZVNQ-UHFFFAOYSA-N |
| Canonical SMILES | CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C |
| Isomeric SMILES | CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C |
| PubChem CID | 11552706 |
| 分子量 | 383.46 |
| 密度 | ~1.2 g/cm3(Predicted) |
|---|---|
| 折光率 | n20D1.58 (Predicted) |
| 沸点 | ~529.4° C at 760 mmHg (Predicted) |
| 熔点 | 258.37° C (Predicted) |
| 分子量 | 383.500 g/mol |
| XLogP3 | 3.800 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 383.201 Da |
| 单同位素质量Monoisotopic Mass | 383.201 Da |
| 拓扑极表面积Topological Polar Surface Area | 71.100 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 573.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| NMR Spectrum 1H | Conforms to Structure |
|---|---|
| Purity(HPLC area) | 98-100(%) |
| 1. O'Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P et al.. (2015) Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.. Am Heart J, 169 (5): (622-630.e6). [PMID:25965709] |
| 2. Oliva J, Galasinski S, Richey A, Campbell AE, Meyers MJ, Modi N, Zhong JW, Tawil R, Tapscott SJ, Sverdrup FM. (2019) Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.. J Pharmacol Exp Ther, 370 (2): (219-230). [PMID:31189728] |
| 3. Rojas LA, Valentine E, Accorsi A, Maglio J, Shen N, Robertson A, Kazmirski S, Rahl P, Tawil R, Cadavid D et al.. (2020) p38α Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy.. J Pharmacol Exp Ther, 374 (3): (489-498). [PMID:32576599] |